Phase 2 Lung Cancer Trial, Recruiting (NCT04322890)

Phase 2 Lung Cancer Trial, Recruiting NCT04322890 Sponsor: Hunan Province Tumor Hospital Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04322890 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who understand what the trial involves and have signed and dated a consent form agreeing to take part
People aged 18 or older
People who have been diagnosed with Stage IV non-small cell lung cancer (a type of lung cancer), confirmed through a tissue or cell sample test
People who have a specific gene mutation (such as EGFR, ALK, ROS1, or similar) confirmed by an approved laboratory
People with a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity (confirm with trial site)
People whose doctors expect them to survive for at least 12 weeks
People whose blood counts and organ function (such as liver and kidneys) are within acceptable levels (confirm with trial site)
People who have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines

Who may not be able to join:

People who do not meet all of the criteria listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yongchang Zhang, MD, Hunan Cancer Hospital

Phone: +8613873123436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04322890

Sponsor: Hunan Province Tumor Hospital

Phase: Phase 2

Status: Recruiting

Condition: Lung Cancer

Trial contact: +8613873123436

More information: https://clinicaltrials.gov/study/NCT04322890

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who understand what the trial involves and have signed and dated a consent form agreeing to take part
People aged 18 or older
People who have been diagnosed with Stage IV non-small cell lung cancer (a type of lung cancer), confirmed through a tissue or cell sample test
People who have a specific gene mutation (such as EGFR, ALK, ROS1, or similar) confirmed by an approved laboratory
People with a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity (confirm with trial site)
People whose doctors expect them to survive for at least 12 weeks
People whose blood counts and organ function (such as liver and kidneys) are within acceptable levels (confirm with trial site)
People who have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines

Who may not be able to join:

People who do not meet all of the criteria listed above

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Hunan Province Tumor Hospital

Registry

ClinicalTrials.gov

Start date

16 April 2020

Est. completion

24 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-free survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov